Cardiovascular risk factors, lipid and glucose levels, and medication use for the study population eligible for stratified analysis
| RIC+pPCI (n=71) | pPCI (n=68) | |
|---|---|---|
| Cardiovascular risk factors | ||
| Age (years) | 63 (±11) | 62 (±11) |
| Male | 57 (80%) | 55 (81%) |
| Smoker | 34 (48%) | 38 (56%) |
| Body mass index (kg/m2) | 26 (±4) | 26 (±4) |
| Diabetes mellitus | 6 (8%) | 8 (12%) |
| Hypertension | 32 (45%) | 19 (28%) |
| Left ventricular hypertrophy | 7 (10%) | 8 (12%) |
| Lipid and glucose levels | ||
| Total cholesterol (mmol/L) | 4.9 (4.1–5.6) | 4.7 (3.8–5.4) |
| LDL cholesterol (mmol/L) | 3.0 (2.3–3.7) | 3.0 (2.2–3.6) |
| Plasma glucose (mmol/L) | 7.7 (6.3–9.9) | 8.0 (6.9–9.5) |
| HbA1c (%) | 5.9 (5.6–6.1) | 5.8 (5.6–6.2) |
| Medication use | ||
| Metformin | 3 (4%) | 3 (4%) |
| Glimepiride | 0 (0%) | 1 (1%) |
| Insulin | 1 (1%) | 2 (3%) |
| β-blockers | 11 (15%) | 10 (15%) |
| ACE inhibitors | 14 (20%) | 6 (9%) |
| ARBs | 10 (14%) | 5 (7%) |
| Long-acting nitrates | 0 (0%) | 0 (0%) |
| Calcium channel blockers | 7 (10%) | 8 (12%) |
| Statins | 12 (17%) | 12 (18%) |
Data are presented as mean (SD), median (IQR) or number (%).
ARBs, angiotensin II receptor blockers; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein; pPCI, primary percutaneous coronary intervention; RIC, remote ischaemic conditioning.